ZA952693B - 1H-indole-3-Glyoxylamide sPLA2 inhibitors - Google Patents

1H-indole-3-Glyoxylamide sPLA2 inhibitors

Info

Publication number
ZA952693B
ZA952693B ZA952693A ZA952693A ZA952693B ZA 952693 B ZA952693 B ZA 952693B ZA 952693 A ZA952693 A ZA 952693A ZA 952693 A ZA952693 A ZA 952693A ZA 952693 B ZA952693 B ZA 952693B
Authority
ZA
South Africa
Prior art keywords
indole
spla2 inhibitors
glyoxylamide spla2
glyoxylamide
sub
Prior art date
Application number
ZA952693A
Other languages
English (en)
Inventor
Nicholas James Bach
Robert Delane Dillard
Susan Elizabeth Draheim
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA952693B publication Critical patent/ZA952693B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA952693A 1994-04-01 1995-03-31 1H-indole-3-Glyoxylamide sPLA2 inhibitors ZA952693B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22191694A 1994-04-01 1994-04-01

Publications (1)

Publication Number Publication Date
ZA952693B true ZA952693B (en) 1996-09-30

Family

ID=22829963

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA952693A ZA952693B (en) 1994-04-01 1995-03-31 1H-indole-3-Glyoxylamide sPLA2 inhibitors

Country Status (29)

Country Link
US (6) US5654326A (xx)
EP (5) EP2341045A1 (xx)
JP (1) JP3109974B2 (xx)
KR (1) KR100368707B1 (xx)
CN (1) CN1067054C (xx)
AT (2) ATE220394T1 (xx)
AU (1) AU688458B2 (xx)
BR (1) BR9501404A (xx)
CA (1) CA2146097C (xx)
CO (1) CO4370099A1 (xx)
CZ (1) CZ82295A3 (xx)
DE (1) DE69527322T2 (xx)
DK (2) DK0675110T3 (xx)
ES (2) ES2377223T3 (xx)
FI (1) FI114793B (xx)
HU (1) HUT72048A (xx)
IL (1) IL113210A (xx)
MX (1) MX9501608A (xx)
MY (1) MY112897A (xx)
NO (1) NO304186B1 (xx)
NZ (1) NZ270848A (xx)
PE (1) PE18696A1 (xx)
PL (1) PL180523B1 (xx)
PT (1) PT675110E (xx)
RU (1) RU2128169C1 (xx)
SI (1) SI0675110T1 (xx)
TW (1) TW383302B (xx)
UA (1) UA47387C2 (xx)
ZA (1) ZA952693B (xx)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA47387C2 (uk) * 1994-04-01 2002-07-15 Елі Ліллі Енд Компані 1H-ІНДОЛ-3-ГЛІОКСИЛАМІДИ ЯК ІНГІБІТОРИ sPLA<sub>2</sub> ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ
JPH08193074A (ja) * 1994-11-18 1996-07-30 Nippon Bayeragrochem Kk 除草性１−シクロプロピルテトラゾリノン類
US6043264A (en) * 1995-01-06 2000-03-28 Toray Industries, Inc. Benzene-condensed heterocyclic derivatives and their uses
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
EP0987250A4 (en) * 1997-02-20 2000-12-06 Shionogi & Co INDOLDICARBONIC ACID DERIVATIVES
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
WO1999009978A1 (en) * 1997-08-28 1999-03-04 Eli Lilly And Company Method for treatment of non-rheumatoid athritis
ES2241178T3 (es) 1997-10-27 2005-10-16 Eli Lilly And Company Profarmacos de ester de morlino-n-etilo de inhibidores indolicos de spla 2.
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
WO1999021545A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
JP2001522883A (ja) * 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
CA2322162A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
ES2253877T3 (es) * 1998-03-03 2006-06-01 SHIONOGI &amp; CO., LTD. Composiciones farmaceuticas que contienen el inhibidor de fosfolipasa((3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1h-indol-4-il)oxi)acetato de sodio.
AU3054399A (en) 1998-03-31 1999-10-25 Shionogi & Co., Ltd. Pyrrolo(1,2-a)pyrazine sPLA2 inhibitor
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
US6407261B1 (en) 1998-04-17 2002-06-18 Eli Lilly And Company Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
WO1999054295A1 (en) * 1998-04-17 1999-10-28 Eli Lilly And Company Process for preparing 4-hydroxy indole, indazole and carbazole compounds
ES2230847T3 (es) * 1998-05-01 2005-05-01 Eli Lilly And Company Esteres inhibidores de spla2.
SK16342000A3 (sk) 1998-05-01 2002-04-04 Eli Lilly And Company Liečivo na liečbu zápalového ochorenia čreva obsahujúce 1H-indol-3-glyoxylamidy
EP1085021A4 (en) 1998-05-21 2003-01-08 Shionogi & Co DERIVATIVES OF PYRROLO 1,2-B] PYRIDAZINE, WITH INHIBITOR EFFECT ON SPLA 2?
CA2338727A1 (en) * 1998-08-03 2000-02-17 Edward David Mihelich Indole spla2 inhibitors
EP1100492B1 (en) * 1998-08-03 2006-05-24 Eli Lilly & Company INDOLE sPLA2 INHIBITORS
AU6240099A (en) 1998-08-24 2000-03-14 Susan E Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
US6576654B1 (en) 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
DZ2771A1 (fr) * 1998-10-09 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
US7098237B1 (en) 1998-10-14 2006-08-29 Shionogi & Co., Ltd. Remedies for ischemia reperfusion injury
US20030149000A1 (en) * 1998-11-10 2003-08-07 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds
JP2002542148A (ja) * 1998-12-21 2002-12-10 イーライ・リリー・アンド・カンパニー 敗血症の処置のための組み合わせ療法
AU2373600A (en) * 1998-12-22 2000-07-12 Eli Lilly And Company Novel spla2 inhibitors
ATE247119T1 (de) * 1998-12-22 2003-08-15 Lilly Co Eli Substituierte pyrroloindole
US6380397B1 (en) 1999-04-15 2002-04-30 Eli Lilly And Company Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6274578B1 (en) 1999-04-20 2001-08-14 Eli Lilly And Company sPLA2 inhibitor ester
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環系化合物
EP1202963B1 (en) * 1999-07-19 2007-01-03 Eli Lilly And Company Spla2 inhibitors
US6673781B1 (en) 1999-08-02 2004-01-06 Shionogi & Co., Ltd. Tricyclic compounds having sPLA2-inhibitory activities
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
WO2001021587A2 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
WO2001026653A1 (fr) * 1999-10-15 2001-04-19 Shionogi & Co., Ltd. Inhibiteurs spla2 du type v et/ou du type x
WO2001036420A1 (fr) 1999-11-15 2001-05-25 Shionogi & Co., Ltd. Derives d'aza-indolizine tricyclique ayant un effet inhibiteur sur spla¿2?
AU2252201A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
AU2050001A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Synthesis of indole-containing spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
EP1259260A1 (en) * 2000-01-06 2002-11-27 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
US20030096854A1 (en) * 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
AU4599601A (en) * 2000-01-07 2001-07-16 Eli Lilly And Company Substituted tricyclics
WO2001066110A2 (en) * 2000-03-09 2001-09-13 Eli Lilly And Company METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS
BR0002188A (pt) * 2000-03-30 2001-11-13 Brasil Compressores Sa Processo de formação do pacote de lâminasmetálicas de estator de motor elétrico e pacotede lâminas metálicas
WO2001081306A2 (en) * 2000-04-19 2001-11-01 Eli Lilly And Company Azide cyclization-based synthesis and intermediates for spla2 inhibitors
WO2002000255A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre le cancer
AU2001267825A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
WO2002000621A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Composes inhibiteurs de la spla2 de type x
WO2002000257A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes a la maladie d'alzheimer
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
AU2001280461A1 (en) * 2000-08-04 2002-02-18 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
US6916840B2 (en) 2000-12-18 2005-07-12 Eli Lilly And Company Spla2 inhibitors
TWI314457B (xx) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
TWI323658B (en) 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
MX2008005660A (es) * 2005-11-03 2008-12-15 Ilypsa Inc Compuestos de indol que tienen sustituyentes c4-amida y uso de los mismos como inhibidores de la fosfolipasa a2.
CA2627349A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-a2 inhibitors
EP1948604A1 (en) * 2005-11-03 2008-07-30 Ilypsa, Inc. Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors
EP1960356A2 (en) 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
JP5198560B2 (ja) * 2008-04-28 2013-05-15 旭化成ファーマ株式会社 フェニルプロピオン酸誘導体及びその用途
CN102271507A (zh) * 2009-01-08 2011-12-07 安塞拉制药有限公司 分泌型磷脂酶a2(spla2)抑制剂和烟酸药物组合物以及治疗心血管疾病和血脂异常的方法
CN106822080A (zh) 2009-04-29 2017-06-13 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN101838232B (zh) * 2009-07-07 2012-02-22 爱斯医药科技(南京)有限公司 Varespladib的制备方法
MA40998A (fr) * 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
WO2017037041A1 (en) * 2015-08-31 2017-03-09 Diaccurate Use of indole compounds to stimulate the immune system

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2825743A (en) 1955-08-30 1958-03-04 Celanese Corp Catalytic hydrogenation of unsaturated aldehydes and ketones
US3242163A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
GB1089071A (en) 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
NL287416A (xx) 1964-04-25
US3449363A (en) 1966-12-22 1969-06-10 American Cyanamid Co 3-substituted 4-trifluoromethyl indoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
US3691194A (en) * 1970-07-30 1972-09-12 Little Inc A 3-indole-glyoxamides
US3686213A (en) 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
US4397850A (en) 1981-10-07 1983-08-09 Sandoz, Inc. Isoxazolyl indolamines
US4552876A (en) * 1984-07-09 1985-11-12 Usv Pharmaceutical Corp. Bisbenzoxazines and pharmaceutical use
US4792555A (en) * 1987-03-20 1988-12-20 American Home Products Corporation Phospholipase A2 inhibitors
NZ234883A (en) * 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5192770A (en) * 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
US5334719A (en) * 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
UA47387C2 (uk) 1994-04-01 2002-07-15 Елі Ліллі Енд Компані 1H-ІНДОЛ-3-ГЛІОКСИЛАМІДИ ЯК ІНГІБІТОРИ sPLA<sub>2</sub> ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
DE69620241T2 (de) * 1995-12-14 2002-10-02 Merck & Co Inc Gonadotropin releasing hormon- antagonisten
PL327132A1 (en) 1995-12-14 1998-11-23 Merck & Co Inc Antagonists of the gonadotrophin liberating hormone
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors

Also Published As

Publication number Publication date
AU688458B2 (en) 1998-03-12
CN1067054C (zh) 2001-06-13
US6175021B1 (en) 2001-01-16
DE69527322D1 (de) 2002-08-14
CN1114310A (zh) 1996-01-03
PE18696A1 (es) 1996-05-30
NZ270848A (en) 1997-05-26
EP0675110A1 (en) 1995-10-04
HUT72048A (en) 1996-03-28
EP0675110B1 (en) 2002-07-10
CA2146097A1 (en) 1995-10-02
CA2146097C (en) 2000-03-21
NO304186B1 (no) 1998-11-09
KR950032117A (ko) 1995-12-20
FI114793B (fi) 2004-12-31
ES2179088T3 (es) 2003-01-16
ATE220394T1 (de) 2002-07-15
AU1621795A (en) 1995-10-12
ATE540923T1 (de) 2012-01-15
US5733923A (en) 1998-03-31
US5654326A (en) 1997-08-05
KR100368707B1 (ko) 2003-06-02
NO951252D0 (no) 1995-03-31
SI0675110T1 (en) 2002-12-31
EP1950200A1 (en) 2008-07-30
PL180523B1 (pl) 2001-02-28
DK1950200T3 (da) 2012-04-10
US6433001B1 (en) 2002-08-13
ES2377223T3 (es) 2012-03-23
UA47387C2 (uk) 2002-07-15
DE69527322T2 (de) 2003-02-27
IL113210A0 (en) 1995-06-29
JPH07285933A (ja) 1995-10-31
EP1197484A2 (en) 2002-04-17
TW383302B (en) 2000-03-01
IL113210A (en) 2001-01-28
PT675110E (pt) 2002-11-29
EP1950200B1 (en) 2012-01-11
EP2341045A1 (en) 2011-07-06
EP1081135A2 (en) 2001-03-07
RU2128169C1 (ru) 1999-03-27
HU9500957D0 (en) 1995-05-29
RU95104885A (ru) 1997-04-27
FI951553A (fi) 1995-10-02
FI951553A0 (fi) 1995-03-31
CO4370099A1 (es) 1996-10-07
BR9501404A (pt) 1996-03-05
PL307951A1 (en) 1995-10-02
US5919943A (en) 1999-07-06
EP1081135A3 (en) 2003-11-05
MX9501608A (es) 1997-02-28
MY112897A (en) 2001-10-31
DK0675110T3 (da) 2002-10-07
NO951252L (no) 1995-10-02
JP3109974B2 (ja) 2000-11-20
US5919810A (en) 1999-07-06
CZ82295A3 (en) 1995-12-13

Similar Documents

Publication Publication Date Title
ZA952693B (en) 1H-indole-3-Glyoxylamide sPLA2 inhibitors
IL130338A0 (en) Pyrroles as sPLA2 inhibitors
HU9401060D0 (en) 1-h-indole-3-acetamide spla2 inhibitors
EP0772596A4 (en) INDOLIZINE SPAL2 INHIBITORS
MX9804751A (es) Naftil acetamidas como inhibidores de la spla2.
EP1100492A4 (en) SPLA 2 INHIBITORS? INDOLE TYPE
IL130201A0 (en) Phenyl glyoxamides as spla2 inhibitors
MX9804750A (es) Naftil glioxamidas como inhibidores de la spla2.
AU5873400A (en) spla2 inhibitors
ATE247119T1 (de) Substituierte pyrroloindole
AU7053700A (en) Novel spla2 inhibitors